| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1177/0961203316651747 |
| P698 | PubMed publication ID | 27225212 |
| P50 | author | Mohammad Hassan A Noureldine | Q57525866 |
| Munther A. Khamashta | Q73418907 | ||
| Ali Haydar | Q85822381 | ||
| Ahmad Sweid | Q88298209 | ||
| P2093 | author name string | I Uthman | |
| M Nader | |||
| A Berjawi | |||
| G Harifi | |||
| J Al Saleh | |||
| R Elnawar | |||
| P2860 | cites work | ILAE official report: a practical clinical definition of epilepsy | Q27009103 |
| Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke | Q28167141 | ||
| Management of the neurological manifestations of APS--what do the trials tell us? | Q28171326 | ||
| Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE) | Q28243974 | ||
| Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis | Q28245345 | ||
| Glutamate receptor GluR3 antibodies and death of cortical cells | Q28261256 | ||
| International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) | Q28292418 | ||
| Cytokines and the nervous system II: Actions and mechanisms of action | Q28301619 | ||
| Malignant hypertension and antiphospholipid antibodies as presenting features of SLE in a young woman using oral contraceptives | Q28324785 | ||
| Rivaroxaban versus warfarin in nonvalvular atrial fibrillation | Q29614696 | ||
| Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration | Q30655992 | ||
| Brain abnormalities in newly diagnosed neuropsychiatric lupus: systematic MRI approach and correlation with clinical and laboratory data in a large multicenter cohort | Q30873630 | ||
| Hughes syndrome, the antiphospholipid syndrome: a new chapter in neurology | Q31001994 | ||
| Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV). | Q31129756 | ||
| Sneddon syndrome with or without antiphospholipid antibodies. A comparative study in 46 patients | Q33329596 | ||
| Isotype distribution and clinical relevance of anti-beta2-glycoprotein I (beta2-GPI) antibodies: importance of IgA isotype | Q33329907 | ||
| Cerebral blood flow and glucose metabolism in multi-infarct-dementia related to primary antiphospholipid antibody syndrome | Q33332894 | ||
| The mystery of Sneddon syndrome: relationship with antiphospholipid syndrome and systemic lupus erythematosus | Q33333901 | ||
| Anti-cardiolipin and anti-beta2 glycoprotein I antibodies in Indian patients with systemic lupus erythematosus: association with the presence of seizures | Q33336296 | ||
| Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients | Q33341941 | ||
| The association of thrombocytopenia with systemic manifestations in the antiphospholipid syndrome | Q33369426 | ||
| Clusters of disease manifestations in patients with antiphospholipid syndrome demonstrated by factor analysis | Q33374901 | ||
| Primary antiphospholipid antibody syndrome presenting with encephalopathy, psychosis and seizures | Q33396284 | ||
| A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome | Q33404206 | ||
| The relevance of "non-criteria" clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features | Q33420116 | ||
| Current treatment of antiphospholipid syndrome: lights and shadows | Q33423959 | ||
| Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies. A mouse model | Q33499900 | ||
| Neuropsychiatric lupus erythematosus, cerebral infarctions, and anticardiolipin antibodies. | Q33562378 | ||
| International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop | Q33685960 | ||
| Ischaemic optic neuropathy, transverse myelitis, and epilepsy in an anti-phospholipid positive patient with systemic lupus erythematosus | Q33733186 | ||
| Diminished white matter integrity in patients with systemic lupus erythematosus | Q34079262 | ||
| The role of cytokines and growth factors in seizures and their sequelae | Q34109710 | ||
| The epidemiology of the epilepsies | Q34296962 | ||
| 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends | Q34400373 | ||
| Poststroke seizures | Q34530025 | ||
| Single photon emission computed tomography and magnetic resonance imaging evaluation in SLE patients with and without neuropsychiatric involvement | Q34740894 | ||
| Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases | Q35071710 | ||
| Encephalitis and antibodies to synaptic and neuronal cell surface proteins. | Q35117077 | ||
| Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughes syndrome). | Q36473943 | ||
| Chorea in the antiphospholipid syndrome. Clinical, radiologic, and immunologic characteristics of 50 patients from our clinics and the recent literature | Q36866914 | ||
| The antiphospholipid syndrome as a neurological disease | Q37549406 | ||
| Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients | Q37803363 | ||
| Autoantibodies associated with diseases of the CNS: new developments and future challenges | Q37903490 | ||
| Neuropsychiatric manifestations in systemic lupus erythematosus: epidemiology, pathophysiology and management | Q37922765 | ||
| Paraneoplastic encephalomyelopathies: pathology and mechanisms | Q37936924 | ||
| Use of new oral anticoagulants in antiphospholipid syndrome | Q38104683 | ||
| Receptors of peptides as therapeutic targets in epilepsy research | Q38164036 | ||
| Hughes syndrome and multiple sclerosis. | Q38261156 | ||
| Antiphospholipid syndrome: an update | Q38410376 | ||
| Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome. | Q38416654 | ||
| Diffusion tensor imaging in patients with acute onset of neuropsychiatric systemic lupus erythematosus: a prospective study of apparent diffusion coefficient, fractional anisotropy values, and eigenvalues in different regions of the brain | Q40234720 | ||
| The syntax of immune-neuroendocrine communication | Q40557484 | ||
| The neuroimaging features of the cardiolipin antibody syndrome | Q40913490 | ||
| Epilepsy: an early symptom of systemic lupus erythematosus | Q42582760 | ||
| High prevalence of antiphospholipid antibodies in children with epilepsy: a controlled study of 50 cases | Q43681755 | ||
| The high prevalence of antiphospholipid antibodies in refractory focal epilepsy is related to recurrent seizures. | Q44469864 | ||
| A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome | Q44588720 | ||
| Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model | Q44652593 | ||
| Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome. | Q45822025 | ||
| Lupus anticoagulant and late onset seizures | Q46862021 | ||
| IgG accumulates in inhibitory hippocampal neurons of experimental antiphospholipid syndrome | Q47611916 | ||
| Frequency of anticardiolipin, antinuclear and anti beta2GP1 antibodies is not increased in unselected epileptic patients: a case-control study. | Q47665064 | ||
| Anticardiolipin and antinuclear antibodies in epilepsy--a population-based cross-sectional study | Q47811982 | ||
| Cytokine-neurotransmitter interactions in the brain. | Q47923993 | ||
| Association between antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus. | Q48144813 | ||
| Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes | Q48245672 | ||
| Antiserum to brain gangliosides produces recurrent epileptiform activity | Q48350462 | ||
| Neurometabolite markers of cerebral injury in the antiphospholipid antibody syndrome of systemic lupus erythematosus. | Q48357005 | ||
| Effects of hemispheric lateralization and site specificity on immune alterations induced by kindled temporal lobe seizures | Q48426826 | ||
| Cerebral magnetic resonance imaging in patients with or without antiphospholipid antibodies | Q48491099 | ||
| Increased myo-inositol in parietal white and gray matter as a biomarker of poor prognosis in neuropsychiatric lupus: a case report | Q48607382 | ||
| Factors at diagnosis predict subsequent occurrence of seizures in systemic lupus erythematosus | Q48709250 | ||
| Magnetic resonance imaging of central nervous system lesions in patients with lupus erythematosus. Correlation with clinical remission and antineurofilament and anticardiolipin antibody titers | Q48752879 | ||
| National General Practice Study of Epilepsy: recurrence after a first seizure | Q48858306 | ||
| In vivo evaluation of brain damage in the course of systemic lupus erythematosus using magnetic resonance spectroscopy, perfusion-weighted and diffusion-tensor imaging | Q48892142 | ||
| Anticardiolipin antibodies in normal subjects. Neuropsychological correlates and MRI findings | Q49226626 | ||
| Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy. | Q50944728 | ||
| Antiphospholipid and glutamic acid decarboxylase antibodies in patients with focal epilepsy. | Q51051407 | ||
| Epileptiform activity evoked by intracerebral injection of anti-brain antibodies | Q51121328 | ||
| Neuropsychiatric manifestations and antiphospholipid antibodies in pediatric onset lupus: 14 years of experience from a tertiary center of North India. | Q51648992 | ||
| Clinical description of seizures in patients with systemic lupus erythematosus. | Q53423288 | ||
| Antiphospholipid and antinuclear antibodies in patients with epilepsy or new-onset seizure disorders. | Q54024916 | ||
| Epileptic seizures in systemic lupus erythematosus | Q57086591 | ||
| P433 | issue | 13 | |
| P304 | page(s) | 1397-1411 | |
| P577 | publication date | 2016-05-25 | |
| P1433 | published in | Lupus | Q6704846 |
| P1476 | title | Hughes syndrome and epilepsy: when to test for antiphospholipid antibodies? | |
| P478 | volume | 25 |
| Q59808719 | Antiphospholipid Syndrome and the Neurologist: From Pathogenesis to Therapy |
| Q91642031 | Antiphospholipid syndrome: a case report with an unusual wide spectrum of clinical manifestations |
| Q47998109 | Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances |
| Q52360896 | Neurological autoantibodies in drug-resistant epilepsy of unknown cause. |
| Q37632131 | Neuropsychiatric Systemic Lupus Erythematosus Involvement: Towards a Tailored Approach to Our Patients? |
| Q89986376 | Pediatric APS: State of the Art |
Search more.